BioTech Health X
  • BioTech News
  • BioTech CEO Interviews
  • BioTech Events
  • BioTech Company Directory
  • Contact Us
Archives
  • May 2023
  • August 2021
  • July 2021
  • April 2021
BioTech Health X
  • BioTech News
  • BioTech CEO Interviews
  • BioTech Events
  • BioTech Company Directory
  • Contact Us

Jak Thomson

8 posts
Studied UC Davis School of Medicine. Enjoy Surfing, Sunning and Helping People. Bylines and analysis in Biotech on major publications. Current Biotech Analyst & Consultant.
Denali Therapeutics Announces Scientific Journal Publication of Preclinical Proof of Concept for Protein Transport Vehicle PTV
Jak Thomson
  • May 31, 2023

Biotech NewsDenali Therapeutics Announces Scientific Journal Publication of Preclinical Proof of Concept for Protein Transport Vehicle (PTV)

  • 2 minute read
Pre-clinical research published in Cell highlights new approach to treat FTD-GRN with enhanced brain uptake of progranulin through…
0 Shares
0
0
0
0
0
0
0
2021 William Blair Biotech Conference
Jak Thomson
  • May 28, 2023

Biotech NewsPresenters Announced for 2021 William Blair Biotech Conference

  • 18 minute read
A wide range of biotechnology companies have announced presentations at the upcoming William Blair Biotech Conference slated to…
0 Shares
0
0
0
0
0
0
0
Aerobiotix Announces Raise of $25M Growth Equity Financing Led by Healthcare Investment Firm Vivo Capital
Jak Thomson
  • May 27, 2023

Biotech NewsAerobiotix Announces Raise of $25M Growth Equity Financing Led by Healthcare Investment Firm Vivo Capital

  • 3 minute read
Aerobiotix, a pioneer in airborne infection control products that provide real-time, in room solutions for hospitals, ASCs, long…
0 Shares
0
0
0
0
0
0
0
BenchSci Expands Advisory Board with New Pharma R&D Leaders
Jak Thomson
  • May 26, 2023

Biotech NewsBenchSci Expands Advisory Board with New Pharma R&D Leaders

  • 2 minute read
BenchSci has welcomed three new members to its advisory board from the pharmacology sector. Steve Hitchcock of Takeda…
0 Shares
0
0
0
0
0
0
0
Indapta Therapeutics Announces Data Demonstrating G-NK Cells Enhance Efficacy in Multiple Myeloma
Jak Thomson
  • May 23, 2023

Biotech NewsIndapta Therapeutics Announces Data Demonstrating G-NK Cells Enhance Efficacy in Multiple Myeloma

  • 4 minute read
Indapta Therapeutics, Inc. today announced the publication of new preclinical data in Blood Advances demonstrating the company’s proprietary…
0 Shares
0
0
0
0
0
0
0
MacroGenics Announces Failure in SOPHIA Study of MARGENZA for Metastatic Breast Cancer Patients
Jak Thomson
  • May 23, 2023

Biotech NewsMacroGenics Announces Failure in SOPHIA Study of MARGENZA for Metastatic Breast Cancer Patients

  • 3 minute read
Biopharma MacroGenics, Inc. (NASDAQ: MGNX) announced that the final overall survival (OS) analysis did not demonstrate a statistically…
0 Shares
0
0
0
0
0
0
0
Exclusive Cel-Sci CEO Geert Kersten Talks Multikine, FDA Approval, CVM Future
Jak Thomson
  • May 23, 2023

BioTech CEO InterviewsExclusive: Cel-Sci CEO Geert Kersten Talks Multikine, FDA Approval, CVM Future

  • 10 minute read
About Cel-Sci Corporation Cel-Sci Corporation is a publicly traded biotechnology business which develops, manufactures, and markets treatments focused…
0 Shares
0
0
0
0
0
0
0
Former Lilly CEO Josh Bilenker & Former Novartis Head of Oncology Jeff Engelman Announce Treeline Biosciences
Jak Thomson
  • April 30, 2021

Biotech NewsEx-Lilly CEO Josh Bilenker & Ex-Novartis Head of Oncology Jeff Engelman Announce Treeline Biosciences

  • 2 minute read
Two powerhouse executives have joined forces to form a brand new cancer Biotech company. Josh Bilenker, M.D., and…
0 Shares
0
0
0
0
0
0
0
Recent Posts
  • Krystal Biotech Announces FDA IND Acceptance for KB407 Cystic Fibrosis Clinical Trial
  • Advanced Chemotherapy Technologies Receives $4 Million NIH Grant to Pursue Pancreatic Cancer Treatment
  • Merck Announces Failure in Keytruda Head and Neck Cancer Phase 3 Clinical Trial
  • Cel-Sci Announces Multikine Immunotherapy Significantly Improves Overall Survival Benefit for Cancer Head & Neck Patients in Phase 3 Trial
  • Denali Therapeutics Announces Scientific Journal Publication of Preclinical Proof of Concept for Protein Transport Vehicle (PTV)
Recent Comments
  • Thomas Shentz on Cellarity Expands Leadership Team to Continue Evolution of Breakthrough Platform to Encode Biology and Purposefully Create New Drugs
  • Tomasz Michałowski on Exclusive: Cel-Sci CEO Geert Kersten Talks Multikine, FDA Approval, CVM Future
  • Presenters Announced for 2021 William Blair Biotech Conference • BioTech Health X on William Blair Biotech Focus Conference 2021 Panel Schedule
Featured Posts
    • May 31, 2023
    Krystal Biotech Announces FDA IND Acceptance for KB407 Cystic Fibrosis Clinical Trial
    Krystal Biotech Announces FDA IND Acceptance for KB407 Cystic Fibrosis Clinical Trial
    • May 31, 2023
    Advanced Chemotherapy Technologies Receives $4 Million NIH Grant to Pursue Pancreatic Cancer Treatment
    Advanced Chemotherapy Technologies Receives 4 Million NIH Grant to Pursue Pancreatic Cancer Treatment
    • May 31, 2023
    Merck Announces Failure in Keytruda Head and Neck Cancer Phase 3 Clinical Trial
    Merck Announces Failure in Keytruda Head and Neck Cancer Phase 3 Clinical Trial
    • May 31, 2023
    Cel-Sci Announces Multikine Immunotherapy Significantly Improves Overall Survival Benefit for Cancer Head & Neck Patients in Phase 3 Trial
    Cel-Sci Announces Multikine Immunotherapy Significantly Improves Overall Survival Benefit for Cancer Head Neck Patients in Phase 3 Trial
    • May 31, 2023
    Denali Therapeutics Announces Scientific Journal Publication of Preclinical Proof of Concept for Protein Transport Vehicle (PTV)
    Denali Therapeutics Announces Scientific Journal Publication of Preclinical Proof of Concept for Protein Transport Vehicle PTV
Recent Posts
  • ImmunityBio Announces FDA Acceptance of BLA for N-803 Anktiva Bladder Cancer Drug
    ImmunityBio Announces FDA Acceptance of BLA for N-803 Anktiva Bladder Cancer Drug
    • May 31, 2023
  • 11/19/21
    • May 30, 2023
  • Repertoire Immune Medicines Enters Collaboration with Yale to Research Multiple Sclerosis Novel Antigen Discovery T Cell Receptors
    Repertoire Immune Medicines Enters Collaboration with Yale to Research Multiple Sclerosis Novel Antigen Discovery & T Cell Receptors
    • May 29, 2023
Categories
  • BioTech CEO Interviews (4)
  • Biotech Info (1)
  • Biotech News (45)
  • Uncategorized (1)
Author
Hello, I’m
BioTech Health X
Follow
BioTech Health X
Designed & Developed by Code Supply Co.
  • Our Contributors
  • List of Modern Life Science Technologies
  • Contact Us
Back to top